Key facts
- It has raised $2.9M; the latest was Seed Round ($5.0M) in Oct 2025.
- Notable investors include US National Science Foundation, Connecticut Innovations, Kineticos Life Sciences Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Diant
- ·The full record, as it builds
Funding rounds
No funding rounds for Diant are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diant
Developer of a nanoparticle technology designed to transform the use of nanoparticles and lipid nanoparticle systems in biopharmaceutical and related industries. The company offers continuous, process-controlled manufacturing platforms that improve the speed, efficiency, and precision of nanoparticle production, enabling pharmaceutical, biotechnology, nutraceutical, food, beverage, and agricultural sectors to accelerate development and enhance product quality.
- Sector
- Healthcare
- HQ
- Manchester, CT, United States
- Founded
- 2019
- Employees
- 8
- Website
- diantpharma.com/
- Ownership
- Privately Held (backing)
Diant doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diant shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diant in its N-PORT filings yet. We sweep new filings monthly.